CoChat

Quetiapine in the Treatment of Anxiety in Patients With Bipolar I or II Depression: A Secondary Analysis From a Randomized, Double-Blind, Placebo-Controlled Study

Hirschfeld, Robert M. A., Weisler, Richard H., Raines, Shane R., Macfadden, Wayne, BOLDER Study Group · 2006 · The Journal of Clinical Psychiatry

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: Quetiapine monotherapy shows efficacy in bipolar depression. The analyses in this multicenter, double-blind, randomized, fixed-dose, placebo-controlled study evaluated effects of quetiapine monotherapy on anxiety symptoms in bipolar depression. METHOD: Of 542 outpatients randomly assigned to treatment, 539 with bipolar I (N = 358) or bipolar II (N = 181) disorder experiencing a major depressive episode (DSM-IV) received 8 weeks of quetiapine monotherapy (600 or 300 mg/day) or placebo between September 2002 and October 2003. Anxiety assessments included the Hamilton Rating Scale for Anxiety (HAM-A) and relevant items from the Montgomery-Asberg Depression Rating Scale (MADRS) and Hamilton Rating Scale for Depression (HAM-D). Analyses evaluated the pooled dose groups versus placebo. RESULTS: At week 8, quetiapine 600 and 300 mg/day each demonstrated significant improvements in HAM-A total score versus placebo (-10.8 and -9.9 vs. -6.7, p < .001). Quetiapine (pooled doses) significantly improved HAM-A total score from week 1. In bipolar I depression, quetiapine showed significant improvement in HAM-A total score versus placebo (-10.4 vs. -5.1, p < .001). In bipolar I depression, quetiapine also showed significant improvements versus placebo on the HAM-A anxious mood and tension items, HAM-A psychic and somatic subscales, MADRS inner tension item, and HAM-D psychic anxiety item (all p < .001), but not the HAM-D somatic anxiety item. In bipolar II depression, quetiapine reduced the HAM-A total score more than placebo, but the difference was not statistically significant (-9.8 vs. -9.0, p = .473). In bipolar II depression, quetiapine showed significant improvement versus placebo on the HAM-A anxious mood, MADRS inner tension, and HAM-D psychic anxiety items (all p < .01). CONCLUSION: Quetiapine monotherapy shows efficacy in treating anxiety symptoms in bipolar I depression; however, the anxiolytic effects in bipolar II disorder require further investigation.

Overview

Integrity signals

Registry

Crossref · 10.4088/jcp.v67n0304

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 24 references

Cited by

See all 116

Metadata

Authors
Hirschfeld, R. M. A., Weisler, R. H., Raines, S. R., Macfadden, W., & BOLDER Study Group
Affiliations
  • The University of Texas Medical Branch at Galveston (US)
  • University of North Carolina at Chapel Hill (US)
  • AstraZeneca (United Kingdom) (GB)
Venue
The Journal of Clinical Psychiatry
Published
2006-03-15
Volume
67
Issue
03
Pages
355-362
ISSN
0160-6689 (ISSN-L)
OpenAlex
W2093305066
Cited by
116
References
23
Citations by year
2026: 1 · 2025: 1 · 2024: 4 · 2023: 5 · 2021: 3 · 2020: 2 · 2019: 5 · 2018: 2 · 2016: 2 · 2015: 13 · 2014: 7 · 2013: 3 · 2012: 9
FWCI
7.95
Type
journal article
Language
en
Open access
closed
Locations
  • The Journal of Clinical Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Keywords
quetiapine, bipolar depression, bipolar I disorder, bipolar II disorder, anxiety symptoms, anxiolytic effects, major depressive episode, Hamilton Anxiety Rating Scale, inner tension
MeSH terms
Quetiapine Fumarate, Adult, Ambulatory Care, Anxiety Disorders, Bipolar Disorder, Major Depressive Disorder, Dibenzothiazepines, Double-Blind Method, Drug Administration Schedule, Female, Humans, Longitudinal Studies, Male, Placebos, Psychiatric Status Rating Scales, Antipsychotic Agents, Comorbidity, Treatment Outcome, Diagnostic and Statistical Manual of Mental Disorders

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Quetiapine in the Treatment of Anxiety in Patients With Bipolar I or II Depression: A Secondary Analysis From a Randomized, Double-Blind, Placebo-Controlled Study. https://app.cochat.ai/papers/10.4088/jcp.v67n0304
The paper
Hirschfeld, R. M. A., Weisler, R. H., Raines, S. R., Macfadden, W., & BOLDER Study Group. (2006). Quetiapine in the Treatment of Anxiety in Patients With Bipolar I or II Depression: A Secondary Analysis From a Randomized, Double-Blind, Placebo-Controlled Study. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.v67n0304

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.